Completed PHASE2 INTERVENTIONAL 3-arm NCT01699464

A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months

Sponsor: Aerie Pharmaceuticals

Conditions Ocular Hypertension Open-angle Glaucoma

Interventions AR-12286 Ophthalmic Solution 0.5% AR-12286 Ophthalmic Solution 0.7% Timolol maleate ophthalmic solution 0.5%

Updated 8 times since 2017 Last updated: Aug 18, 2023 Started: Oct 31, 2012 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ocular Hypertension and Open-angle Glaucoma and is currently completed. Aerie Pharmaceuticals leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Sep 2023 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aerie Pharmaceuticals

Data source: Aerie Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.